Provided by Tiger Trade Technology Pte. Ltd.

Hoth Therapeutics

1.02
+0.04004.08%
Post-market: 1.020.00000.00%19:09 EST
Volume:713.90K
Turnover:732.48K
Market Cap:15.82M
PE:-1.01
High:1.06
Open:1.00
Low:0.9602
Close:0.9800
52wk High:2.12
52wk Low:0.6554
Shares:15.51M
Float Shares:14.96M
Volume Ratio:0.61
T/O Rate:4.77%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0134
EPS(LYR):-1.2844
ROE:-151.13%
ROA:-84.46%
PB:1.92
PE(LYR):-0.79

Loading ...

Hoth Therapeutics Receives USPTO Notice of Allowance for Novel Exon-Skipping Therapy Patent Targeting Allergic Diseases

Reuters
·
Feb 12

BUZZ-Hoth Therapeutics rises as early obesity‑drug data in mice shows promise

Reuters
·
Feb 10

BRIEF-Hoth Therapeutics Announces Groundbreaking Positive Results Hoth's Ht-Va Gdnf Surpasses Semaglutide In Weight Loss

Reuters
·
Feb 10

Hoth Therapeutics Announces Groundbreaking Positive Results: Hoth's Ht-Va Gdnf Surpasses Semaglutide in Weight Loss, Glucose Control, and Liver Health in Obesity Model

THOMSON REUTERS
·
Feb 10

Hoth Therapeutics Inc - Gdnf Attenuates Weight Gain by 10-15% Leading to a Plateau in the Final Weeks of Treatment

THOMSON REUTERS
·
Feb 10

Hoth Therapeutics Inc - Gdnf Reduces Liver Weight by 20-30%

THOMSON REUTERS
·
Feb 10

EXCLUSIVE: Small Biotech Hoth Therapeutics Claims Experimental Obesity Drug Topped Famed Wegovy In Preclinical Study

Benzinga
·
Feb 10

Hoth Therapeutics Confirms It Holds No Cryptocurrency Assets

Reuters
·
Feb 05

Hoth Therapeutics Addresses Market Rumor, Hoth Holds No Crypto Currency Assets

THOMSON REUTERS
·
Feb 05

BRIEF-Hoth Therapeutics Delivers 100% Clinical Response With ~50% Reduction In Disease Severity In Open-Label PK Cohort Of EGFR-Treated Cancer Patients

Reuters
·
Jan 22

Hoth Therapeutics Inc - Additional Endpoints Show ~34% Improvement in Oncology Toxicity

THOMSON REUTERS
·
Jan 22

Hoth Therapeutics Inc - Ht-001 Well Tolerated With No Unexpected Safety Signals

THOMSON REUTERS
·
Jan 22

Hoth Therapeutics Delivers 100% Clinical Response With ~50% Reduction in Disease Severity in Open-Label Pk Cohort of Egfr-Treated Cancer Patients

THOMSON REUTERS
·
Jan 22

Hoth Therapeutics Secures Chinese Patent for HT-KIT Cancer Program, Strengthening Global Oncology IP Portfolio

Reuters
·
Jan 21

BRIEF-Hoth Therapeutics Reaches Key EU Regulatory Inflection Point Advancing Ht-001 Oncology Trial Toward Multi-Country Site Activation

Reuters
·
Jan 15

Hoth Therapeutics : Country-Specific Part Ii Regulatory Decisions in Hungary, Spain, & Poland Are Expected by Jan 19, 2026

THOMSON REUTERS
·
Jan 15

Hoth Therapeutics Receives Positive EU Regulatory Conclusion for HT-001 Oncology Trial

Reuters
·
Jan 15

Sector Update: Health Care Stocks Mixed in Afternoon Trading

MT Newswires Live
·
Jan 03

Hoth Therapeutics Files Two US Provisional Patents for Oncology-Focused Dermatology Platform; Shares Rise

MT Newswires Live
·
Jan 02

Hoth Therapeutics Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Dec 05, 2025